Beyond the numbers: The silent decades before the first heart attack

A perspective on preventive cardiology in the era of cardio-metabolic syndrome.

A 52-year-old man arrives at the Emergency Department with crushing central chest pain. His electrocardiogram confirms an anterior ST-elevation myocardial infarction (STEMI), and coronary angiography reveals an occluded proximal left anterior descending artery. As cardiologists, our focus is clear: restore coronary blood flow as quickly as possible.

But perhaps the more important question is this: When did his disease actually begin? Certainly not on the morning he developed chest pain. His cardiovascular (CV) journey probably started 15 or even 20 years earlier—with gradual weight gain, increasing visceral adiposity, insulin resistance, borderline hypertension, worsening dyslipidaemia, fatty liver, and chronic low-grade inflammation. Each abnormality appeared modest in isolation, yet together they quietly remodelled his vasculature, myocardium and kidneys long before his first symptom.^1-3

The myocardial infarction was not the beginning of his disease. It was simply its loudest manifestation. This is the challenge—and opportunity—of modern preventive cardiology. For decades, CV prevention has been organised around individual risk factors. Hypertension is treated separately from diabetes, dyslipidaemia from obesity, and chronic kidney disease from cardiovascular disease (CVD). Yet, accumulating evidence tells us that these conditions rarely exist in isolation. Rather, they are interconnected manifestations of a common pathophysiological process driven by visceral adiposity, insulin resistance, chronic inflammation, endothelial dysfunction and neurohormonal activation.^2,3

Cardiometabolic syndrome represents more than the coexistence of obesity, hypertension, dyslipidaemia and type 2 diabetes. These disorders frequently arise from shared biological pathways and amplify each other’s effects, accelerating atherosclerotic CVD, heart failure, atrial fibrillation and chronic kidney disease. The emerging concept of cardiovascular-kidney-metabolic (CKM) syndrome further reinforces the close relationship between metabolic dysfunction, kidney disease and CVD as part of a continuous disease spectrum.¹

This shift in understanding demands a corresponding shift in clinical practice. Prevention should no longer be defined simply by achieving target blood pressure, LDL cholesterol or glycated haemoglobin values. Those numbers remain important, but they represent only individual pieces of a much larger puzzle. The objective should be to identify the entire cardiometabolic risk profile before irreversible organ damage occurs.

Risk assessment should, therefore, extend beyond traditional CV risk factors. Waist circumference, renal function, metabolic dysfunction-associated steatotic liver disease (MASLD), family history, lipoprotein(a), physical inactivity and lifetime CV risk all deserve attention. In selected individuals, coronary artery calcium scoring may further identify subclinical atherosclerosis and refine preventive strategies beyond conventional risk calculators.²

Lifestyle intervention remains the cornerstone of preventive cardiology. Even modest weight reduction can improve blood pressure, insulin sensitivity, lipid profiles and inflammatory markers. Dietary patterns rich in vegetables, fruits, whole grains, legumes, lean proteins and unsaturated fats, together with regular aerobic and resistance exercise, smoking cessation and adequate sleep, should be considered fundamental CV therapies rather than optional lifestyle advice.^2,3,7

At the same time, pharmacological management has entered a new era. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated CV and renal benefits extending beyond glucose lowering, fundamentally changing how we approach patients with cardiometabolic disease. These therapies reinforce an important principle: we are no longer treating isolated diseases—we are modifying an interconnected biological process.^4-6

Equally important is the recognition of residual CV risk. Many patients achieve guideline-recommended LDL cholesterol and blood pressure targets yet continue to experience CV events because obesity, insulin resistance, chronic inflammation or hypertriglyceridaemia remain inadequately addressed. Treating numbers alone is no longer enough. Increasingly, we are moving beyond biomarker management to address the interconnected mechanisms that drive cardiometabolic disease.^2,8

As obesity, type 2 diabetes and MASLD continue to rise globally, cardiometabolic syndrome is emerging as one of the defining healthcare challenges of our generation. The greatest gains in CV medicine over the coming decades are unlikely to come solely from more sophisticated stents or increasingly complex structural interventions. They will come from recognising disease earlier, intervening before irreversible organ damage develops, and preventing the first CV event.

The future of preventive cardiology will move beyond a one-size-fits-all approach toward personalised risk assessment and intervention. Two individuals with the same LDL cholesterol, blood pressure or HbA_1c may have very different CV trajectories because their underlying biology, genetics, environment and lifestyle exposures are unique. Integrating clinical factors with emerging tools such as lipoprotein(a), genetic risk profiles, metabolic phenotyping, imaging biomarkers and digital health data may allow earlier identification of individuals at greatest risk.

The goal is not simply to treat abnormal numbers, but to understand each patient’s evolving cardiometabolic landscape and intervene at the stage when disease remains preventable. Personalised prevention represents the transition from reactive CV care to proactive health preservation—identifying who needs prevention, when to intervene, and how aggressively to act in order to prevent CVD before it becomes clinically apparent.

One lesson has become increasingly clear: The most successful procedure is the one that never needs to be performed. Every patient presenting with STEMI reminds us that the disease did not begin in the coronary artery that morning. It began years earlier, progressing silently through the interconnected pathways of cardiometabolic dysfunction. The first heart attack is rarely the beginning of CVD. More often, it is the consequence of opportunities missed. The future of cardiology will not be defined only by how well we treat myocardial infarction. It will be defined by how many myocardial infarctions that never happen.